HIGHLIGHTS
- who: Jesse Fishman and colleagues from the Inc, Waltham, MA, USA have published the Article: Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network, in the Journal: (JOURNAL) of 20/08/2021
- what: Since this study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data, this study was not required to undergo Institutional Review Board approval. identified patient records and did not involve the collection, use . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.